India, May 19 -- Clearmind Medicine Inc. (CMND) has approved a 1-for-10 reverse stock split as part of its plan to regain compliance with Nasdaq's minimum bid price requirement, with the adjustment set to take effect on May 21, 2026.
The clinical-stage biotech company, which develops non-hallucinogenic, second-generation neuroplastogen-derived therapeutics, said the reverse split will consolidate its issued and outstanding common shares from 10,190,337 to approximately 1,019,033, subject to rounding for fractional shares. No fractional shares will be issued, and any fractional amounts will be rounded up to the nearest whole share.
The company noted that its authorized share capital will remain unchanged following the adjustment, and propo...